ARYx up after ATI-7505 data

ARYx (NASDAQ:ARYX) gained $0.46 to $6.68 on Friday after reporting that 80 mg oral ATI-7505 twice daily met the primary endpoint of total number of spontaneous bowel movements (SBMs) during the first seven days vs. placebo in the Phase IIb 2007003 trial to treat chronic idiopathic constipation (3.32 vs. 0.31, p=0.0031). The double-blind, international trial, which was terminated last month after Procter & Gamble (NYSE:PG) exercised an option to return rights to the cisapride analog serotonin (5-HT4) receptor agonist, enrolled 214 patients out of the planned 400 (See BioCentury Extra, Thursday, July 03, 2008). ...